Sarepta Therapeutics (NASDAQ:SRPT) Stock Crosses Above Two Hundred Day Moving Average – Time to Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $18.68 and traded as high as $19.28. Sarepta Therapeutics shares last traded at $18.99, with a volume of 1,481,904 shares traded.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of analyst reports. William Blair raised shares of Sarepta Therapeutics to a “hold” rating in a research note on Wednesday, September 23rd. Royal Bank Of Canada lowered their target price on Sarepta Therapeutics from $19.00 to $17.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 8th. Weiss Ratings lowered shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. HC Wainwright reissued a “sell” rating and set a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 5th. Finally, Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, September 28th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and seven have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $23.71.

Sarepta Therapeutics Stock Up 2.4%

The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of -6.55, a price-to-earnings-growth ratio of 0.34 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The business’s 50 day moving average is $19.24 and its 200-day moving average is $18.68.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. The company had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same period last year, the business posted $2.02 earnings per share. The firm’s revenue was down 34.3% compared to the same quarter last year. Equities analysts anticipate that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the business. Fulcrum Asset Management LLP increased its holdings in Sarepta Therapeutics by 14,895.9% during the 3rd quarter. Fulcrum Asset Management LLP now owns 73,180 shares of the biotechnology company’s stock valued at $1,364,000 after purchasing an additional 72,692 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in shares of Sarepta Therapeutics by 4,355.1% during the third quarter. Pictet Asset Management Holding SA now owns 689,732 shares of the biotechnology company’s stock valued at $12,567,000 after acquiring an additional 674,250 shares during the period. Privium Fund Management B.V. raised its holdings in Sarepta Therapeutics by 22.1% during the 3rd quarter. Privium Fund Management B.V. now owns 166,605 shares of the biotechnology company’s stock worth $3,036,000 after purchasing an additional 30,105 shares during the last quarter. Alps Advisors Inc. lifted its position in Sarepta Therapeutics by 31.3% during the 3rd quarter. Alps Advisors Inc. now owns 139,944 shares of the biotechnology company’s stock valued at $2,550,000 after purchasing an additional 33,395 shares during the period. Finally, CenterBook Partners LP grew its holdings in Sarepta Therapeutics by 232.3% during the 3rd quarter. CenterBook Partners LP now owns 153,853 shares of the biotechnology company’s stock worth $2,803,000 after acquiring an additional 107,560 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.